Peptide name : CM–FA

Source/Organism : Synthetic analogue

Linear/Cyclic : Linear

Chirality : L

Peptide length: 27

C-terminal modification: Linear

N-terminal modification : Amidation

Non-natural peptide information:

Assay type : MTT assay

Assay time : 24-h

Activity : IC50 = 10.38 µg/mL

Cell line : MCF-7

Cancer type : Breast Cancer

Other activity : Antibacterial

Amino acid composition bar chart :

Molecular mass : 2950.59 Dalton

Aliphatic index : 1.3

Instability index : 43.4444

Hydrophobicity (GRAVY) : 0.3556

Isoelectric point : 11.105

Charge (pH 7) : 4.7472

Aromaticity : 3.703

Molar extinction coefficient (cysteine, cystine): (1, 0)

Hydrophobic/hydrophilic ratio : 1.7

hydrophobic moment : -1.09

Missing amino acid : D,E,F,H,M,N,Y

Most occurring amino acid : L

Most occurring amino acid frequency : 4

Least occurring amino acid : C

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (33., 18., 44.)

SMILES Notation: CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CS)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C

1 : Sahsuvar S, et al. Development and pharmaceutical investigation of novel cervical cancer-targeting and redox-responsive melittin conjugates. Sci Rep. 2023; 13:18225. doi: 10.1038/s41598-023-45537-x

Paper title : Development and pharmaceutical investigation of novel cervical cancer-targeting and redox-responsive melittin conjugates.

Doi : https://doi.org/10.1038/s41598-023-45537-x

Abstract : Cervical cancer has recently become one of the most prevalent cancers among women throughout the world. Traditional cancer therapies generate side effects due to off-target toxicity. Thus, novel cancer medications coupled with suitable drug delivery systems are required to improve cancer therapies. Melittin peptide has a high affinity to disrupt cancer cells. In this study, we designed targeted and redox-responsive Melittin conjugates for cervical cancer and then tested them in vitro. Folic acid and squamous cell carcinoma-specific peptide (CKQNLAEG) were used as targeting agents to design various conjugates. Our findings indicate that both anticancer conjugates were effective against different cancer cell lines, including MCF-7, C33A, and HeLa. Moreover, these conjugates were found to have antioxidant and antibacterial effects as well as reduced hemolytic activity. The CM-Target (N-terminus cysteine modified-Melittin-targeting peptide-functionalized conjugate) has become more stable and acted specifically against squamous cell carcinoma, whereas folic acid (FA)-containing conjugates acted efficiently against all cancer types studied, especially for breast cancer. According to our results, these anticancer conjugates may be possible anticancer drug candidates that have fewer adverse effects.